PASTIC Dspace Repository

Chewable cough tablets with improved palatability: A comparative phase II clinical trial

Show simple item record

dc.contributor.author Khan, Mehwish
dc.contributor.author Rehman, Hina
dc.contributor.author Naveed, Safila
dc.contributor.author Zaidi, Syed Faisal
dc.contributor.author Ayaz, Sultan
dc.contributor.author Owais, Aymen
dc.contributor.author Usmanghani, Khan
dc.date.accessioned 2022-12-13T10:00:21Z
dc.date.available 2022-12-13T10:00:21Z
dc.date.issued 2019-01-15
dc.identifier.citation Khan, M., Rehman, H., Naveed, S., Zaidi, S. F., Ayaz, S., Owais, A., & Usmanghani, K. (2019). Chewable cough tablets with improved palatability: A comparative phase II clinical trial. Pakistan Journal of Pharmaceutical Sciences, 32. en_US
dc.identifier.issn 1011-601X
dc.identifier.uri http://142.54.178.187:9060/xmlui/handle/123456789/15011
dc.description.abstract Cough is the common disease condition which affects patients of every age. Numerous OTC medications available in community pharmacies however no antiviral treatment and even antibiotics has been shown to be effective without pre-existing lung infection. The treatment approach of medicinal herbs has been recognized for many decades and even longer for the treatment and prevention of cough. The aim of this study was to evaluate the safety and efficacy of Mukalbion poly herbal chewable tablets for the treatment of cough with improved palatability against a marketed brand (Poly herbal). For the formulation development of test group, the herbs were supplied by the Procurement department of Herbion Pakistan Pvt. Ltd. Althea officinalis (roots), Hedera helix (leaves) and Sisymbrium irio (seeds) were used for the manufacturing of Mukalbion (poly herbal, test group) chewable tablet. The comparative control clinical trial was carried out during a time frame of 07 months with sample size of 70 patients as per epidemiological software for sample size and each group contained 35 (±5) patients. Chewable tablets were administered and evaluated for effectiveness after 15 days of treatment. The data were collected by the patients through clinical trial questionnaire. The validated quality of life questionnaire (LCQ) was also used for assessment. The results were analyzed by applying paired sample T test by using IBM SPSS version 20.00. The p value was ≤0.005 at 95% confidence interval for cough variables including cough bouts, viscosity of sputum, chest congestion, sore throat and shortness of breath. The LCQ cough scale score was higher in test group as compared to control group. The test group also showed well tolerated in term of palatability. None of the patient claimed any of the side effects and no compliance were observed against the marketed brand. en_US
dc.language.iso en en_US
dc.publisher Karachi: Faculty of Pharmacy & Pharmaceutical Sciences University of Karachi en_US
dc.subject Chewable cough tablets en_US
dc.subject palatability en_US
dc.subject polyherbal ingredients en_US
dc.subject Phase II clinical trial. en_US
dc.title Chewable cough tablets with improved palatability: A comparative phase II clinical trial en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account